Health · 5 views
Trial Results Show 'Something We Have Not Seen for Years' in Osteosarcoma
(MedPage Today) -- The investigational antibody-drug conjugate (ADC) risvutatug rezetecan (Ris-Rez) significantly improved progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, the phase III ARTEMIS-011…
Summary
(MedPage Today) -- The investigational antibody-drug conjugate (ADC) risvutatug rezetecan (Ris-Rez) significantly improved progression-free survival (PFS) in patients with relapsed or refractory osteosarcoma, the phase III ARTEMIS-011 trial from
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- Nurse-led program shown to improve midlife dementia risk profiles in new studyContinue reading
- Live Webinar October 29: Should We Let Robots Be Doctors?Continue reading
- Donate your body later and your blood now | Brief lettersContinue reading
- Cardiologist-Prime Minister? LDL Pill Eyed for Diabetes; Second Tricuspid TEER OK'dContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow